There is substantial evidence that an effective HIV vaccine to combat the AIDS epidemic must target the tremendous diversity of the HIV envelope glycoprotein. Our contention is that a multiple-envelope vaccine that elicits immune responses to a diversity of envelope epitopes will generate broad protection against naturally occurring viral isolates. Support for this hypothesis is provided by preliminary clinical trials of our PolyEnve1 vaccine, which presents 23 different envelopes in the form of recombinant vaccinia viruses. The development of approaches to enhancing the effectiveness of PolyEnv1 is now a primary goal. Our preliminary studies in a mouse model strongly supports the comprehensive evaluation of a multi- step strategy in which envelopes are first administered as DNA, than as recombinant vaccinia viruses, and finally as purified protein (i.e., a D-V-P regimen incorporating PolyEnv1, 23 matching envelopes in the form of DNA, and a selected subset of 6 envelopes as purified protein. Monoclonal antibodies to facilitate the typing of immune responses will be generated to the purified proteins, the diversity of responses to the protein component of the DNA component alone will be evaluated, and the magnitude and diversity of the response to the complete D-V-P regimen will be assessed. The second part of this project will address the phenomenon of """"""""original antigenic sin"""""""", whereby boosting immunizations with variant molecules serve only to enhance antibody responses to epitopes that are shared with the priming antigen, and are less effective in eliciting responses to novel epitopes. Experiments will be conducted to test the hypothesis that the D-V- P vaccination strategy will circumvent """"""""original antigen sin"""""""" and generate an optimally diverse antibody response. The studies described in this project are an important step towards realizing the potential of multiple-envelope HIV vaccines.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Sealy, Robert E; Jones, Bart G; Surman, Sherri L et al. (2016) Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins. Viral Immunol 29:64-70
Jones, Bart G; Sealy, Robert E; Zhan, Xiaoyan et al. (2012) UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV. Vaccine 30:3188-95
Surman, Sherri L; Rudraraju, Rajeev; Woodland, David L et al. (2011) Clonally related CD8+ T cells responsible for rapid population of both diffuse nasal-associated lymphoid tissue and lung after respiratory virus infection. J Immunol 187:835-41
Hurwitz, Julia L (2011) Respiratory syncytial virus vaccine development. Expert Rev Vaccines 10:1415-33
Surman, Sherri L; Brown, Scott A; Jones, Bart G et al. (2010) Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin. AIDS Res Hum Retroviruses 26:783-93
Brown, Scott A; Surman, Sherri L; Sealy, Robert et al. (2010) Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses 2:435-467
Sealy, Robert; Zhan, Xiaoyan; Lockey, Timothy D et al. (2009) SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development? Curr HIV Res 7:497-503
Sealy, Robert; Slobod, Karen S; Flynn, Patricia et al. (2009) Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int Rev Immunol 28:49-68
Surman, Sherri L; Sealy, Robert; Jones, Bart G et al. (2009) HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen. Hum Vaccin 5:268-71
Sealy, Robert; Jones, Bart G; Surman, Sherri L et al. (2009) Short communication: The dead cell: a potent escort for HIV type 1 transinfection. AIDS Res Hum Retroviruses 25:1123-8

Showing the most recent 10 out of 31 publications